HPHA.F Heidelberg Pharma AG

Healthcare Biotechnology Frankfurt Exchange
2.05 EUR
Close of Nov 13, 2026
1.93 3.33
Market cap
EUR 96.0M
P/E
-
P/B
7.63x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Aug 2026.

Is HPHA.F undervalued?

Graham number

The Graham number of Heidelberg Pharma AG cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Heidelberg Pharma AG fundamental analysis

No fundamental analysis for Heidelberg Pharma AG yet.

Heidelberg Pharma AG stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Heidelberg Pharma AG

Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, Europe, China, the United States, and internationally. The company's lead product candidates include HDP-101, an anti-BCMA antibody, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It also develops HDP-102, an antibody and the compound Amanitin, which has completed preclinical development for the trea…

Full company profile